# Aclarion, Inc.

Aclarion, Inc. is a public company headquartered in Broomfield, CO, United States.

## Company overview

- **Legal name:** Aclarion, Inc.
- **Former names in filing history:** Nocimed, Inc. (2015-03-03 to 2021-10-26)
- **Classification:** Public company
- **Industry (SIC):** 8071 — Services-Medical Laboratories
- **Headquarters:** Broomfield, CO, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001635077

## About

Aclarion develops healthcare technology that processes magnetic resonance spectroscopy data into biomarkers for assessing chronic low back pain. Its Nociscan system is intended to support clinical decisions about discogenic pain, including surgical planning. The company also researches ways to relate spectral measurements to clinical outcomes. Those research aims do not establish an approved treatment or a demonstrated improvement in patient outcomes. Its reported principal executive office is in Broomfield, CO (United States). For fiscal 2025, ended 2025-12-31, its originally reported results included revenue of USD 75,730; a net loss of USD 7,233,629; cash used in operations of USD 7,164,204. At that year-end, it reported total assets of USD 13,672,404 and cash and cash equivalents of USD 12,015,789. Historical figures retain the originally filed amounts where later comparative figures differ.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2025 (period ended 2025-12-31)

- **Revenue:** $75,730 (USD 75,730)
- **Net income:** -$7.2M (USD -7,233,629)
- **Total assets:** $13.7M (USD 13,672,404)
- **Cash and equivalents:** $12.0M (USD 12,015,789)
- **Operating cash flow:** -$7.2M (USD -7,164,204)

### FY2024 (period ended 2024-12-31)

- **Revenue:** $45,724 (USD 45,724)
- **Net income:** -$7.0M (USD -6,992,927)
- **Total assets:** $2.1M (USD 2,123,483)
- **Cash and equivalents:** $453,661 (USD 453,661)
- **Operating cash flow:** -$5.3M (USD -5,271,609)

### FY2023 (period ended 2023-12-31)

- **Revenue:** $75,404 (USD 75,404)
- **Net income:** -$4.9M (USD -4,911,374)
- **Total assets:** $2.5M (USD 2,459,774)
- **Cash and equivalents:** $1.0M (USD 1,021,069)
- **Operating cash flow:** -$3.6M (USD -3,646,947)

### FY2022 (period ended 2022-12-31)

- **Revenue:** $60,444 (USD 60,444)
- **Net income:** -$7.6M (USD -7,605,542)
- **Total assets:** $3.2M (USD 3,205,961)
- **Cash and equivalents:** $1.5M (USD 1,472,806)
- **Operating cash flow:** -$5.3M (USD -5,314,171)
- **Later filings:** Net income, Total assets, Operating cash flow: shown as originally filed; later filings report different values for the same periods.

## Recent SEC filings

- Form 10-Q — filed 2026-08-06 — period 2026-06-30 — FORM 10-Q FOR JUN 2026
- Form 8-K — filed 2026-06-04 — period 2026-06-04 — CURRENT REPORT
- Form 10-Q — filed 2026-05-13 — period 2026-03-31 — FORM 10-Q FOR MAR 2026
- Form DEF 14A — filed 2026-04-27 — period 2026-06-04 — NOTICE AND PROXY STATEMENT
- Form 8-K — filed 2026-04-22 — period 2026-04-21 — FORM 8-K
- Form 8-K — filed 2026-03-19 — period 2026-03-19 — FORM 8-K
- Form 10-K — filed 2026-03-18 — period 2025-12-31 — FORM 10-K FOR DEC 2025
- Form 8-K — filed 2026-01-13 — period 2026-01-09 — CURRENT REPORT
- Form 8-K — filed 2026-01-09 — period 2026-01-08 — CURRENT REPORT
- Form 10-Q — filed 2025-11-12 — period 2025-09-30 — FORM 10-Q FOR SEP 2025
- Form 8-K — filed 2025-10-14 — period 2025-10-13 — FORM 8-K
- Form 8-K — filed 2025-09-03 — period 2025-09-02 — CURRENT REPORT

---

Updated: 2026-10-15T21:34:01.423Z

Canonical page: https://altss.com/profile/aclarion-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology